Weight-Loss Efficacy of GLP-1 Receptor Agonists Relative to Lifestyle-Based Interventions

ABSTRACT This clinical review compares the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with traditional lifestyle modifications in managing obesity. This article also examines barriers to accessing the medications in both civilian and veteran populations. This clinical review was conducted through a wide-ranging review of the published literature, including clinical trials, observational studies, and review articles on lifestyle modifications, GLP-1 receptor agonists, and barriers to obesity treatment. While lifestyle modifications are generally considered a first-line approach and are cost-effective, they tend to yield only modest weight loss. In contrast, GLP-1 RAs offer significantly greater reductions in body weight as evidenced by recent clinical trials. These medications can have minor but uncomfortable side effects and offer benefits beyond weight loss. Despite their effectiveness, many patients struggle to obtain these medications due to high costs and stringent insurance requirements. Access is particularly challenging within the Veterans Affairs Medical Center, where patients may wait months to complete mandatory lifestyle-modification classes before becoming eligible. This review also emphasizes the need for further research comparing GLP-1 RAs directly with lifestyle interventions, exploring combined treatment approaches, and assessing long-term cost-effectiveness. Ultimately, GLP-1 Medications provide superior weight-loss outcomes, and overcoming barriers to access is crucial to optimizing patient care.